UT-MD Anderson Cancer Center: Combination of Dual-Targeted Therapies and Chemotherapy Shows High Response Rates in BRAF-Mutated Metastatic Colorectal Cancer
January 27, 2025
January 27, 2025
HOUSTON, Texas, Jan. 27 (TNSres) -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations
ABSTRACT: 16 (https://meetings.asco.org/abstracts-presentations/241160)
* * *
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted t . . .
* * *
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations
ABSTRACT: 16 (https://meetings.asco.org/abstracts-presentations/241160)
* * *
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted t . . .